Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma

BACKGROUND: We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly called ABT-414, plus radiation and temozolomide in newly diagnosed glioblastoma (arm A). The purpose of this study was to evaluate the safety and pharmacokinetics of dep...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Gan, Hui K, Reardon, David A, Lassman, Andrew B, Merrell, Ryan, van den Bent, Martin, Butowski, Nicholas, Lwin, Zarnie, Wheeler, Helen, Fichtel, Lisa, Scott, Andrew M, Gomez, Erica J, Fischer, JuDee, Mandich, Helen, Xiong, Hao, Lee, Ho-Jin, Munasinghe, Wijith P, Roberts-Rapp, Lisa A, Ansell, Peter J, Holen, Kyle D, Kumthekar, Priya
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2018
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5961429/
https://ncbi.nlm.nih.gov/pubmed/29077941
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox202
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi